Transenterix Inc (NASDAQ:TRXC) Expected to Post Quarterly Sales of $870,000.00
Equities analysts expect Transenterix Inc (NASDAQ:TRXC) to report sales of $870,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Transenterix’s earnings, with the highest sales estimate coming in at $1.68 million and the lowest estimate coming in at $60,000.00. Transenterix reported sales of -$999.00 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 100.1%. The firm is expected to issue its next earnings report on Friday, August 4th.
According to Zacks, analysts expect that Transenterix will report full year sales of $870,000.00 for the current fiscal year, with estimates ranging from $6.26 million to $8.26 million. For the next year, analysts expect that the firm will post sales of $33.78 million per share, with estimates ranging from $16.60 million to $49.90 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Transenterix.
A number of equities research analysts have commented on the stock. B. Riley downgraded shares of Transenterix to a “neutral” rating and set a $0.70 price objective on the stock. in a research report on Tuesday, May 16th. Zacks Investment Research downgraded shares of Transenterix from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th.
Shares of Transenterix (NASDAQ TRXC) traded up 10.6420% during midday trading on Friday, reaching $0.6893. 662,712 shares of the company’s stock traded hands. The stock’s market capitalization is $102.38 million. The firm’s 50-day moving average price is $0.56 and its 200 day moving average price is $1.07. Transenterix has a 1-year low of $0.45 and a 1-year high of $2.33.
In other news, Director Richard C. Pfenniger, Jr. acquired 100,000 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were bought at an average cost of $0.54 per share, with a total value of $54,000.00. Following the transaction, the director now owns 148,000 shares in the company, valued at approximately $79,920. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.